Current Concepts in Surgical Pathology 2020

Overview

GDANSK

Mark your Calendar and Save the Date as Surgical Pathology, Oncology & Artificial Intelligence (A.I)
come together at this first of its kind International Medical Conference
to be held in Gdansk, Poland June 4, 5 & 6 2020.

Conference Description & Goals:

This cutting edge conference is a ‘must attend’ for Pathologists, Oncologists, Surgeons and Physicians in general who are interested in Advances in Cancer Diagnosis, Precision Oncology and how Medical Informatics is powering the future of Cancer Diagnosis and Treatment. Over the last decade great advances have been made in diagnostic pathology and in treatment options for patients suffering from malignant neoplasms. In great measure, such advances have been generated by the use of molecular techniques, which can help find better mechanisms for targeted therapies. In addition, the current use of bioinformatics has in itself created a different way of communicating and gathering information about different possibilities that not only impact diagnosis but also treatment.

Based on those recent developments, the conference will not only showcase state of the art diagnostic approach to different tumoral conditions in different anatomical areas, but also will present more current information on molecular techniques, the use of bioinformatics, artificial intelligence (A.I.) and precision medicine. Needless to say, each of these areas come together to create an incredible synergy in the treatment options that a patient may have. Therefore, all the lectures will be given by expert pathologists in their respective field as well as by experts in these modern techniques. Additionally, the lectures on treatment options will be given by experienced expert oncologists.

The most important Goals for this conference are:

  • To understand the different pathological conditions that need to be considered in the differential diagnosis of tumoral conditions.
  • To understand the morphological, immunohistochemical and molecular approach to tumour pathology.
  • To gain knowledge in current information regarding the advances of bioinformatics, artificial intelligence (A.I.) and therapeutics.
  • To understand the impact on the treatment of different pathological conditions.
  • To get acquainted with more current nomenclatures and advanced techniques.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

04.06.2020 — 6.00

05.06.2020 — 7.00

06.06.2020 — 3.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.


EACCME

EACCME
European Accreditation Council for Continuing Medical Education

Conference Fees

Early birds Until 29th February 2020 350 €
Regular registration

Until 3rd June 2020

400 €
Onsite registration Only by credit card 450 €
Students*   100 €

*A valid student ID must be presented on site at the reception desk.

The registration fee includes:

  • participation in academic sessions and companies exhibition,
  • conference materials,
  • refreshments during breaks,
  • lunch,
  • ID badge.

Before paying the registration fee, it is required to register in the electronic conference system, choosing the REGISTRATION bookmark.

The registration fee should be paid to the following bank account or by PayPal.

VM Media sp. z o.o. VM Group sp. k.
ul. Świętokrzyska 73, 80–180 Gdańsk
Bank BGŻ BNP Paribas S.A. o. Gdańsk (SWIFT CODE PPABPLPK)
NR IBAN: PL 15 1600 1303 0004 1007 1035 9021; SWIFT; PPABPLPK

Please quote: “PATHOLOGY2020, [name and surname]” as the bank transfer title.

 

 

Conditions of withdrawal**

Should you decide to withdraw your participation, please inform the Organizer by regular mail or by e-mail: pathology@viamedica.pl.

Should you withdraw, you are entitled to receive a refund of the fee from which a manipulation fee will be deducted, as follows:

  • if you inform us about your withdrawal after you have made the payment, 30 days before the conference or earlier, 10% will be deducted from your refund,
  • if you inform us about your withdrawal between 15 and 29 days before the conference, 35% will be deducted from your refund,
  • if you inform us about your withdrawal 14 days before the conference or later, you will not be entitled to a refund.

 

Scientific & Organizational Board

Cesar Moran, MD (Conference Director)
Wojciech Biernat, MD
Marcin Matuszewski, MD
Janusz Popaszkiewicz, MD
Łukasz Stolarczyk, MD

 

Faculty

Click on the selected name to learn more.

  • Cesar Moran, MD — MD Anderson Cancer Center 

    Cesar A. Moran, MD

    Dr. Moran is currently the Chief of Thoracic Pathology at M D Anderson Cancer Center in Houston Texas, USA. Dr. Moran is a world recognized expert in thoracic pathology and specifically, he is one of the top world experts in mediastinal tumors. Over the course of his career, he has authored more than 350 peer review manuscripts, more than 50 chapters in surgical pathology textbooks, and 10 books devoted to thoracic pathology. In addition, Dr. Moran is the Editor-in-Chief for Annals of Diagnostic Pathology and serves in the editorial board of several other journals of pathology. Dr. Moran has lectured throughout the world as an invited speaker. Dr. Moran’s name has been appended to a histological classification of thymic epithelial tumors as well as to the staging of these tumors.

    X
  • Dipen Maru, MD — MD Anderson Cancer Center 

    Dipen Maru, MD

    Dr. Dipen Maru is a Professor of Pathology and Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. He is an expert Gastrointestinal Pathologist with more than 160 publications in gastroesophageal or colorectal neoplasms and is a principle investigator of peer reviewed funded projects from National Cancer Institute and Cancer Prevention Research Institute of Texas. He has authored and edited Armed Forces Institute of Pathology Atlas on Non-neoplastic Gastrointestinal Diseases and written multiple book chapters. As an invited speaker at several international conferences and teaching institutions, Dr. Maru has shared MD Anderson pathology practice guidelines in upper and lower gastrointestinal neoplasms.

    X
  • Don Lynn Gibbons, MD — MD Anderson Cancer Center 

    Don L. Gibbons, MD, PhD

    Dr. Gibbons graduated from Harvard University in 1993 (BA, with honors in Biochemistry), and obtained his MD and PhD degrees from Albert Einstein College of Medicine in 2004. Dr. Gibbons completed his Internal Medicine Residency at Baylor College of Medicine before joining MD Anderson Cancer Center in 2006 as a Clinical Fellow and later as a Research Fellow and Instructor. In 2010, he was appointed Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology, with a secondary appointment in the Department of Molecular and Cellular Oncology, and promoted to Associate Professor in 2016. Dr. Gibbons is a physician-scientist, specializing in lung cancer medical oncology and with a lab investigating the unique characteristics of the tumor microenvironment and mechanisms that drive metastasis, including how cancer cells orchestrate immune evasion. He was selected for the Physician Scientist Award (2012-2014), the R. Lee Clark Fellowship (2014-2016), the Young Physician-Scientist Award by the American Society of Clinical Investigation (2014), and the Waun Ki Hong Excellence in Team Science Award (2017). Dr. Gibbons is the Director of the Thoracic/Head and Neck Medical Oncology Translational Genetic Models Laboratory and a Co-Leader of the Lung Cancer Moon Shot Program at MD Anderson Cancer Center. His translational research focuses on understanding the determinants of sensitivity and resistance to immune checkpoint therapies and has driven the development of new clinical trials, particularly in the use of combinations that incorporate immunotherapy.

    X
  • Esther C. Yoon, MD — MD Anderson Cancer Center

    Esther C. Yoon, MD

    Dr. Yoon’s educational background includes a B.S. in Integrated Science from the University of British Columbia and an M.D. from St. George’s University of Medicine. Her postdoctoral training included a combined Anatomic and Clinical Pathology residency at the Westchester Medical Center / New York Medical College where she served as a Chief Resident. She completed a combined breast and gynecological surgical pathology at New York University Langone Medical Center where she was honored as the Fellow of the Year, and a Cytopathology fellowship at Yale New Haven Hospital. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Cytopathology.

    Dr. Yoon’s research interests include triple negative breast cancers, chemotherapy resistance, and biomarkers. She has authored numerous publications and presented at regional and national level conferences. She is an active member of the United States and Canadian Academy of Pathology (USCAP) through the mentor / mentee and ambassador programs. Dr. Yoon is currently an Assistant Professor at M.D. Anderson Cancer Center, practicing breast pathology and cytopathology.
    X
  • Piotr Borkowski, MD  — Quest Diagnostics

    Piotr Borkowski, MD

    Dr. Piotr Borkowski attended and graduated from the Medical University in Gdansk in 1990. He has over 25 years of experience in diagnostic tissue pathology, research, teaching, molecular diagnostics and computerized image analysis.

    From 1990-1993 he took a postdoctoral research fellowship at the University of Maryland and the National Institutes of Health studying molecular aspects of growth factors in atherosclerosis and digital image processing and analysis. For his work on TGF-beta 1 gene expression and associated computerized analysis, Dr. Borkowski received the prestigious Stowell-Orbison Award.

    From 1993 to 1996 he was a resident in anatomic and clinical pathology, and the Chief Resident (1996-97) at Mount Sinai Medical Center, Miami Beach, Florida. While a resident, he was awarded a Cardiovascular Research Grant as a Primary Investigator and also received scientific honors including the Klausner Award for Best Basic Research Paper (’94,’96) and the Sidney Israel Resident in Pathology Award (’97).

    From 1997-2001, Dr. Borkowski worked in a hospital based private practice as a Staff Pathologist for St. Joseph Hospital in Port Charlotte, Florida and then Parkway Regional Medical Center, North Miami Beach, Florida.

    In 2001, Dr. Borkowski joined Quest Diagnostics and continues to serve as a Senior Staff Pathologist specializing in Uropathology, Gastrointestinal pathology, Women’s Health Pathology and Clinical Informatics. His practice also involves expert consultation service, computerized breast prognostic markers analysis and novel uses of machine learning and analytic microscopy in the diagnosis and prognosis of cancer. His current aims are utilizing Digital Pathology and Artificial Intelligence (A.I.) to advance precision diagnosis, work flow, productivity and personalized care in prostate, urinary bladder, breast and gastrointestinal cancer.

    X
  • Rachel M. Layman, MD — MD Anderson Cancer Center 

    Rachel M. Layman, MD

    Dr. Layman is an Associate Professor in the Department of Breast Medical Oncology at the MD Anderson Cancer Center in Houston, Texas, USA. She received her medical degree at Case Western Reserve University and completed her Hematology and Oncology Fellowship at the University of Michigan. At MD Anderson, Dr. Layman provides treatment of breast cancer patients in her active medical practice and is actively engaged in clinical and translation research. Her primary research interest is hormone receptor positive breast cancer. She is interested in determining mechanisms of resistance to endocrine therapy, development of improved treatments, and enhanced selection of treatment for individual patients. She has authored numerous publications based on her past and ongoing research.

    X
  • Ronald Przygodzki, MD  — US Department of Veterans Affairs 

    Ronald M. Przygodzki, MD

    Ronald M. Przygodzki, MD is Director of Genomic Medicine R&D at the Office or Research and Development for the US Department of Veterans Affairs, Washington, DC. He holds a degree in medicine from the Medical University of Warsaw, Poland. He is board certified in anatomic and clinical pathology (American Board of Pathology), with subspecialization in molecular genetic pathology (American Board of Pathology and American Board of Medical Genetics). He has over 25 years of research and clinical experience with over 15 years of administrative experience. His previous leadership roles (private and public sectors) include the position of Director, Biomedical Laboratories R&D at the US Department of Veterans Affairs, as Chief of Pathology at the Children's National Medical Center and as Associate Director of the Molecular Diagnostics Laboratory at the Armed Forces Institute of Pathology, Washington DC. He conceptualized, drafted and guided implementation of the Million Veterans Program, one of the largest mega-biobank worldwide. Dr. Przygodzki's research expertise and interests are in anatomic and clinical pathology and molecular genomics, spanning from the theoretical to practical clinically translatable arenas. He has developed unique molecular-based techniques around the use of small archival tissue specimens typically found in pathology. He has authored numerous publications, book chapters, and books. His molecular pathology research efforts have allowed him to receive national and international recognition. His current aims are building bridges between bench research-to-clinical use including targeting pharmacogenomic combinatorial analyses to help guide therapies.

    X
  • Shi-Ming Tu, MD — MD Anderson Cancer Center 

    Shi-Ming Tu, MD

    Dr. Tu is a clinical professor of Genitourinary Medical Oncology at M.D. Anderson Cancer Center in Houston, Texas, USA. He is a clinician, researcher, educator, and author. He specializes in the care of patients with prostate and testicular cancers. His research interests include stem-cell origin of variant prostate cancers and mixed germ cell tumors, management of residual disease in solid tumors. He has authored more than 110 peer-reviewed manuscripts. His books, Origin of Cancers: Clinical Perspectives and Implications of a Stem-Cell Theory of Cancer and Story of Hydra: Portrait of Cancer as a Stem-Cell Disease, were published by Springer in 2010 and by Nova in 2019, respectively.

    X

 

Participants

The conference is for Pathologists, Oncologists, Surgeons and Physicians in general  who care for patients with Neoplastic conditions and are interested in Advances in Cancer Diagnosis,  Precision Oncology and how Medical Informatics is powering the future of Cancer Diagnosis and Treatment.

The conference language will be English.

 


**The above conditions do not apply to natural persons as consumers within the meaning of Article 221 the Polish Civil Code of April 23, 1964 (Journal of Laws, No.16, item 93) of February 9, 2017 (Journal of Laws of 2017, item 459,  amended).

Organizer:
Via Medica
Media patronage :
Via Medica
Partner:
Via Medica

Strony konferencji Grupy Via Medica wykorzystują pliki cookies. Opcje dotyczące cookies można zmienić w ustawieniach przeglądarki internetowej.
Korzystanie z niniejszej strony bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie www.wszystkoociasteczkach.pl

Copyright © 2019 Via Medica | Kariera w Grupie Via Medica